Mechanism of Action: Phosphodiesterase 3 Inhibitors

Drugs with Mechanism of Action: Phosphodiesterase 3 Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd	OHTUVAYRE	ensifentrine	SUSPENSION;INHALATION	217389-001	Jun 26, 2024		RX	Yes	Yes			Y
Msd	OHTUVAYRE	ensifentrine	SUSPENSION;INHALATION	217389-001	Jun 26, 2024		RX	Yes	Yes				Y
Msd	OHTUVAYRE	ensifentrine	SUSPENSION;INHALATION	217389-001	Jun 26, 2024		RX	Yes	Yes			Y
Msd	OHTUVAYRE	ensifentrine	SUSPENSION;INHALATION	217389-001	Jun 26, 2024		RX	Yes	Yes			Y
Msd	OHTUVAYRE	ensifentrine	SUSPENSION;INHALATION	217389-001	Jun 26, 2024		RX	Yes	Yes			Y
Msd	OHTUVAYRE	ensifentrine	SUSPENSION;INHALATION	217389-001	Jun 26, 2024		RX	Yes	Yes

Last updated: July 9, 2026

ecutive summary
Phosphodiesterase 3 (PDE3) inhibitors concentrate market risk in a small, well-defined class: milrinone for short-term acute heart failure, and oral agents in the “PDE3 inhibitor” category that have materially limited ongoing growth (notably cilostazol in PAD). Patent and exclusivity positions are dominated by older small-molecule filings whose core compositions and key formulations largely exited or are near exit in major markets. The near-term competitive pressure is therefore more driven by product life cycle (brand vs generic, formulation line extensions, and device or administration-specific IP) than by new, expansive molecular protection.

Scope note on this analysis (what “PDE3 inhibitors” means here)
This landscape addresses PDE3 inhibitors with established clinical and commercial presence: milrinone, cilostazol, and structurally related PDE3 inhibitor drugs used for cardiovascular and peripheral vascular indications. The dominant patent patterns across the class are composition-of-matter and known-use method-of-use claims (cardiac inotropy and vasodilation), with incremental protection via controlled-release formulations, salt/particle engineering, and packaging/administration methods where brands persisted.

---

What patents protect PDE3 inhibitors like milrinone and cilostazol?

Core claim types in the PDE3 inhibitor estate

Across the PDE3 inhibitor class, protection typically clusters into four buckets:

1. Composition of matter
   Broad compounds or specific chemical series and salts. For older molecules, these are the first to expire or become narrow via prosecution history and validity challenges.

2. Method of use (indication and dosing regimen)
   Claims for acute heart failure management (milrinone-like inotropy) or antiplatelet benefit in PAD (cilostazol-like indications). These often survive longer where the brand retains a specific labeled regimen or a particular patient subgroup.

3. Formulations
   Oral controlled release, particle size control, salts optimized for bioavailability, and sometimes pediatric-friendly formulations.

4. Manufacturing and process
   Less prominent for the most mature molecules, but still used to delay generic entry via process-specific limitations.

How many patents cover PDE3 inhibitors?

For mature PDE3 inhibitor drugs, the usable “active” patent inventory in practice is often a subset of the original filing portfolio:

• Milrinone: limited remaining formulation/process or secondary patents in some geographies if the primary composition expired long ago. Litigation history in many markets has tended to focus on formulation and method-of-use rather than chemistry.
• Cilostazol: composition has been long expired in most major jurisdictions. The remaining enforceable perimeter is typically formulation and method-of-use around specific dosing forms or clinical use expansions, depending on local Orange Book or patent register status.

---

Which companies hold the patent rights for PDE3 inhibitors today?

Brand originators vs successors

For PDE3 inhibitors, patent ownership has frequently shifted through:

• corporate restructuring of original brand developers,
• rights transfers tied to regional launches,
• acquisition of legacy portfolios.

Practically, the “current rightsholders” in enforcement are the firms controlling:

• marketed product dossiers,
• listed patents in the relevant reference registries (for US, Orange Book),
• and regional patent families that remained enforceable after term adjustments.

What typically dominates ownership

• For milrinone, the active enforceable rights (where any remain) generally sit with the entity marketing the specific branded injectable or with successor holders of secondary patents.
• For cilostazol, most enforcement leverage tends to sit with originator or regional license holders for any late-expiring formulation and method-of-use claims, while basic composition claims are usually not the main barrier for generics.

---

What is the Orange Book status of milrinone and cilostazol?

Orange Book listings: how to interpret the risk

In the US, the Orange Book status drives the Paragraph IV pathway for ANDA filers:

• Listed patents covering drug substance or drug product can block initial ANDA approval if still listed and not carved out by noninfringement/non-effectiveness arguments.
• Method-of-use patents apply if the ANDA’s proposed label would infringe.

For mature PDE3 inhibitors, the typical situation is:

• Composition-of-matter patents are largely expired.
• Remaining Orange Book activity is often limited to formulation or use-related listed patents, with fewer active barriers by time compared with newer MOAs.

Practical outcome for ANDA filers

• If no active Orange Book patents remain for the reference product for a given strength/dosage form, generics can often enter with fewer Hatch-Waxman obstacles.
• If method-of-use patents are still listed for a particular indication, generics can still face litigation or label carve-out requirements.

---

When do PDE3 inhibitor patents lose exclusivity in the US and EU?

Exclusivity timeline mechanics

Two “clocks” matter:

1. Patent term expiration (including any term adjustments where applicable).
2. Regulatory exclusivities (data exclusivity and market exclusivity), which for older small molecules generally do not extend far beyond patent terms.

Class-level pattern

Because PDE3 inhibitors are generally older small molecules:

• primary exclusivity ended years earlier in the US and EU,
• leaving a longer tail dominated by formulation and method-of-use patents that vary by dosage form and region.

Timing implication for market entry

Near-term generic and biosimilar risk is not driven by “first patent loss” but by:

• the last remaining listed formulation or use patent in a particular strength,
• any ongoing litigation settlements that delay launch,
• and the availability of “skinny labels” that avoid method-of-use infringement.

---

What generic entry risks exist for PDE3 inhibitors?

Most common entry barriers

For PDE3 inhibitors, generics most often encounter barriers tied to:

• formulation claims (controlled-release, specific salt forms, particle size specifications),
• method-of-use claims (indication or dosing that is still protected),
• and process claims that limit how the generic can manufacture to meet claim constraints.

Why “Paragraph IV” may still matter even with older assets

Even when composition patents are expired, Paragraph IV can still be used if:

• method-of-use patents are listed for the reference product label scope, or
• formulation patents remain enforceable.

Competition outcomes

• In settings where listed patents are already off the Orange Book or expired, generics typically launch quickly and drive down unit prices.
• Where method-of-use is still listed, the generic may:
  • pursue design-around,
  • accept a label carve-out,
  • or enter via a settlement that defines permitted claims and launch timing.

---

What patent litigation affects milrinone and cilostazol?

Litigation pattern in PDE3

PDE3 inhibitor litigation tends to concentrate on:

• infringement of formulation/process patents for specific dosage forms,
• infringement of method-of-use patents tied to labeled cardiovascular or PAD indications,
• invalidity arguments around obviousness, lack of novelty, or overbroad claim construction.

How to map litigation to commercial risk

Litigation affects market dynamics through:

• potential automatic 30-month stays after first Paragraph IV filings,
• design-around work that delays manufacturing scale-up for a generic entrant,
• settlements that set launch calendars, market allocation (less common), or scope limitations on indications.

---

How do PDE3 inhibitors compare with other cardiovascular MOAs in patent durability?

PDE3 vs PDE5 vs beta-agonists: different patent decay curves

• PDE5 inhibitors (eg, sildenafil/tadalafil) often have large, active composition and formulation estates in some regions historically, but their core assets also reached maturity.
• Beta-agonists and other inotropes show fragmentation across salts, formulations, and delivery devices.

The practical point for PDE3 inhibitors:

• Many remain in mature lifecycle stages.
• Brand protection relies more on product form and label scope than on broad chemical novelty.

---

What formulations are protected for PDE3 inhibitors?

Milrinone injectable: formulation and administration claims

For injectable PDE3 inhibitors, remaining protection (where present) is typically:

• stability-related formulation claims,
• vehicle composition or concentration constraints,
• and sometimes manufacturing process steps tied to sterility assurance.

Cilostazol oral: controlled-release and particle engineering

For oral PDE3 inhibitors like cilostazol:

• extended-release formulations and specific excipient systems are common targets for secondary patenting,
• as are particle size and dissolution profile controls aimed at bioavailability and tolerability.

Design-around pathways

Generic formulation design-around often requires:

• demonstrating non-infringement of specific formulation claim parameters,
• or filing under a non-infringing strength/formulation not covered by the listed patents.

---

Which Paragraph IV challenges are most likely for PDE3 inhibitor brands?

Likelihood drivers

The highest likelihood of Paragraph IV filings exists where:

• the reference product still has listed formulation or method-of-use patents,
• the generic can propose a label that triggers method-of-use patents or can file for a carve-out,
• and the last listed patents are near expiration, making it economically rational to litigate.

Most likely claim targets

• method-of-use: infringement based on dosing and indication,
• formulation: identical or near-identical excipient system and dissolution profile,
• process: steps that enable bioequivalence.

---

Is there biosimilar risk for PDE3 inhibitors?

Answer: no biosimilar market structure

PDE3 inhibitors are small molecules, not biologics. Biosimilar frameworks do not apply. Competitive risk is primarily:

• ANDA generics for oral solids and injectables,
• authorized generics,
• and cross-brand switching if multiple marketed products exist with comparable dosing and label scope.

---

What commercial dynamics shape PDE3 inhibitor pricing and volume?

Milrinone: hospital-centric volume and tender dynamics

Milrinone-like injectable PDE3 inhibitors are typically:

• used in acute settings (ICU, perioperative, acute decompensated heart failure),
• priced under institutional procurement and tendering,
• affected by supply continuity and manufacturing capacity.

Patent-driven pricing power tends to be narrower than in chronic oral therapies because:

• substitution decisions are influenced by formulation compatibility, stability, and procurement policies,
• generic approvals can shift hospital formularies quickly once exclusivity ends.

Cilostazol: chronic adherence and generic penetration

For cilostazol-like oral agents in PAD:

• chronic dosing enables rapid generic substitution where patents are not actively protecting the marketed form,
• payer coverage and step therapy can affect patient persistence.

When generics enter:

• unit price compresses,
• brand may preserve share only through formulary positioning, clinician familiarity, and any remaining formulation/label differentiation.

---

Key patent-and-market checkpoints: how to model the next competitive window

Checkpoint 1: last listed patent by dosage form

Competitive entry accelerates when:

• all Orange Book-listed patents are expired or no longer cover the exact NDC/strength.

Checkpoint 2: method-of-use vs drug product coverage

Even after drug product protection ends:

• method-of-use patents can preserve exclusivity-like effects by constraining generic labeling.

Checkpoint 3: settlement-driven launch calendars

Litigation settlements in Hatch-Waxman contexts often:

• specify permitted launch dates,
• limit label scope,
• and impose non-adjudication terms or covenant conditions.

Checkpoint 4: manufacturing/IP barriers

For formulation-protected injectables and modified-release oral products:

• bioequivalence and stability testing timelines can delay generic commercialization even when patents expire.

---

Key Takeaways

• PDE3 inhibitor market dynamics are driven by late-cycle patent tails tied to formulation and method-of-use rather than by ongoing molecular exclusivity.
• In the US, the Orange Book status of each specific strength and dosage form is the highest signal for generic entry timing and Paragraph IV risk.
• Milrinone’s hospital procurement structure typically limits long-lived pricing power; cilostazol’s oral chronic use can see faster generic share shifts once remaining formulation/label patents clear.
• Competitive risk is predominantly Hatch-Waxman ANDA litigation and design-around of formulation/process claims, not biosimilar pathways.

---

FAQs

1) What is the most common patent type that blocks generic PDE3 inhibitor entry?

Method-of-use and drug-product formulation patents tied to specific dosage forms and label scope.

2) Can a generic launch PDE3 inhibitors with a label carve-out?

Yes, when method-of-use patents are listed and the generic can propose non-infringing labeling consistent with FDA labeling requirements and patent scope.

3) Do manufacturing process patents matter for PDE3 inhibitor generics?

They can, especially for injectable stability and sterility-related controls or for formulation manufacturing steps that map to claim language.

4) Are PDE3 inhibitors at biosimilar risk?

No. PDE3 inhibitors are small molecules; competition comes through ANDAs and authorized generics.

5) What market signals indicate the next PDE3 inhibitor patent cliff?

Orange Book “listed patent” status by NDC and strength, plus any ongoing district court litigation or settlement-defined launch dates affecting generic timing.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Drug Trials Snapshots. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots
3. European Medicines Agency. (n.d.). Product information and EPAR data. https://www.ema.europa.eu/
4. United States Patent and Trademark Office. (n.d.). Patent term adjustment and related concepts. https://www.uspto.gov/